Guggenheim > Rydex Variable Trust
Biotechnology Fund
$12.71M
Avg Monthly Net Assets
$11.00M
Total Assets
$35K
Total Liabilities
$10.97M
Net Assets
Biotechnology Fund is an Underlying fund in Rydex Variable Trust
from Guggenheim,
based in Maryland,
United States of America.
The fund has one share class
and monthly net assets of $12.71M.
On August 28th, 2024 it reported 72 holdings, the largest
being AbbVie Inc (8.3%), Amgen Inc (6.3%) and Gilead Sciences Inc (4.5%).
Data provided by Fincoded.
Share Classes
| Name | Class/Contract ID | Ticker | Monthly Returns (2 years) |
|---|---|---|---|
| Variable Annuity | C000010380 |
Holdings
From latest NPORT-P, filed August 28th, 2024 for period ending June 30th, 2024.
Historic holdings data available from Fincoded.
| Name | Profile | Category | Country | Value $USD | # Shares | % of Fund |
|---|---|---|---|---|---|---|
| AbbVie, Inc. (AbbVie Inc) | Long | Equity-common | US | $908K | 5K | 8.28 |
| ACADIA Pharmaceuticals, Inc. (ACADIA Pharmaceuticals Inc) | Long | Equity-common | US | $75K | 5K | 0.68 |
| Akero Therapeutics, Inc. (Akero Therapeutics Inc) | Long | Equity-common | US | $60K | 3K | 0.55 |
| Alkermes plc | Long | Equity-common | US | $140K | 6K | 1.27 |
| Alnylam Pharmaceuticals, Inc. (Alnylam Pharmaceuticals Inc) | Long | Equity-common | US | $350K | 1K | 3.19 |
| Amgen, Inc. (Amgen Inc) | Long | Equity-common | US | $686K | 2K | 6.26 |
| Amicus Therapeutics, Inc. (Amicus Therapeutics Inc) | Long | Equity-common | US | $84K | 8K | 0.76 |
| Apellis Pharmaceuticals, Inc. (Apellis Pharmaceuticals Inc) | Long | Equity-common | US | $92K | 2K | 0.84 |
| Ardelyx, Inc. (Ardelyx Inc) | Long | Equity-common | US | $72K | 10K | 0.65 |
| Argenx SE | Long | Equity-common | NL | $151K | 352 | 1.38 |
| Arrowhead Pharmaceuticals, Inc. (Arrowhead Pharmaceuticals Inc) | Long | Equity-common | US | $91K | 4K | 0.83 |
| AstraZeneca plc | Long | Equity-common | GB | $286K | 4K | 2.61 |
| Axsome Therapeutics, Inc. (Axsome Therapeutics Inc) | Long | Equity-common | US | $97K | 1K | 0.89 |
| Beam Therapeutics, Inc. (Beam Therapeutics Inc) | Long | Equity-common | US | $64K | 3K | 0.58 |
| Biogen, Inc. (Biogen Inc) | Long | Equity-common | US | $295K | 1K | 2.69 |
| BioMarin Pharmaceutical, Inc. (BioMarin Pharmaceutical Inc) | Long | Equity-common | US | $201K | 2K | 1.83 |
| BioNTech SE | Long | Equity-common | DE | $98K | 1K | 0.89 |
| Blueprint Medicines Corp. | Long | Equity-common | US | $102K | 942 | 0.93 |
| BofA Securities, Inc. | Long | Repurchase agreement | US | $15K | – | 0.13 |
| Bridgebio Pharma, Inc. (Bridgebio Pharma Inc) | Long | Equity-common | US | $90K | 4K | 0.82 |
| Cerevel Therapeutics Holdings, Inc. | Long | Equity-common | US | $90K | 2K | 0.82 |
| Corteva, Inc. (Corteva Inc) | Long | Equity-common | US | $322K | 6K | 2.93 |
| Crinetics Pharmaceuticals, Inc. (Crinetics Pharmaceuticals Inc) | Long | Equity-common | US | $91K | 2K | 0.83 |
| CRISPR Therapeutics AG | Long | Equity-common | US | $114K | 2K | 1.04 |
| Cytokinetics, Inc. (Cytokinetics Inc) | Long | Equity-common | US | $128K | 2K | 1.17 |
| Dynavax Technologies Corp. | Long | Equity-common | US | $60K | 5K | 0.55 |
| Exact Sciences Corp. | Long | Equity-common | US | $144K | 3K | 1.31 |
| Exelixis, Inc. (Exelixis Inc) | Long | Equity-common | US | $131K | 6K | 1.20 |
| First American Government Obligations Fund - Class X (First American Funds) | Long | Short-term investment vehicle | US | $16K | 16K | 0.14 |
| Gilead Sciences, Inc. (Gilead Sciences Inc) | Long | Equity-common | US | $490K | 7K | 4.46 |
| GRAIL, Inc. (GRAIL Inc) | Long | Equity-common | US | $5K | 325 | 0.05 |
| Guardant Health, Inc. (Guardant Health Inc) | Long | Equity-common | US | $92K | 3K | 0.84 |
| Halozyme Therapeutics, Inc. (Halozyme Therapeutics Inc) | Long | Equity-common | US | $137K | 3K | 1.25 |
| Illumina, Inc. (Illumina Inc) | Long | Equity-common | US | $204K | 2K | 1.86 |
| Immunovant, Inc. (Immunovant Inc) | Long | Equity-common | US | $67K | 3K | 0.61 |
| Incyte Corp. | Long | Equity-common | US | $172K | 3K | 1.57 |
| Insmed, Inc. (Insmed Inc) | Long | Equity-common | US | $174K | 3K | 1.58 |
| Intellia Therapeutics, Inc. (Intellia Therapeutics Inc) | Long | Equity-common | US | $67K | 3K | 0.61 |
| Intra-Cellular Therapies, Inc. (Intra-Cellular Therapies Inc) | Long | Equity-common | US | $134K | 2K | 1.22 |
| Ionis Pharmaceuticals, Inc. (Ionis Pharmaceuticals Inc) | Long | Equity-common | US | $137K | 3K | 1.25 |
| Iovance Biotherapeutics, Inc. (Iovance Biotherapeutics Inc) | Long | Equity-common | US | $73K | 9K | 0.66 |
| Ironwood Pharmaceuticals, Inc. (Ironwood Pharmaceuticals Inc) | Long | Equity-common | US | $51K | 8K | 0.46 |
| J.P. Morgan Securities LLC | Long | Repurchase agreement | US | $19K | – | 0.17 |
| Jazz Pharmaceuticals plc | Long | Equity-common | US | $126K | 1K | 1.15 |
| Krystal Biotech, Inc. (Krystal Biotech Inc) | Long | Equity-common | US | $73K | 400 | 0.67 |
| Legend Biotech Corp. | Long | Equity-common | KY | $148K | 3K | 1.35 |
| Madrigal Pharmaceuticals, Inc. (Madrigal Pharmaceuticals Inc) | Long | Equity-common | US | $66K | 236 | 0.60 |
| Medpace Holdings, Inc. (Medpace Holdings Inc) | Long | Equity-common | US | $140K | 340 | 1.28 |
| Moderna, Inc. (Moderna Inc) | Long | Equity-common | US | $295K | 2K | 2.68 |
| Natera, Inc. (Natera Inc) | Long | Equity-common | US | $180K | 2K | 1.64 |
| Neurocrine Biosciences, Inc. (Neurocrine Biosciences Inc) | Long | Equity-common | US | $189K | 1K | 1.72 |
| Novavax, Inc. (Novavax Inc) | Long | Equity-common | US | $62K | 5K | 0.57 |
| Nuvalent, Inc. (Nuvalent Inc) | Long | Equity-common | US | $62K | 819 | 0.57 |
| Pacific Biosciences of California, Inc. | Long | Equity-common | US | $14K | 10K | 0.13 |
| Prothena Corporation plc (Prothena Corp PLC) | Long | Equity-common | US | $81K | 4K | 0.74 |
| PTC Therapeutics, Inc. (PTC Therapeutics Inc) | Long | Equity-common | US | $66K | 2K | 0.60 |
| Recursion Pharmaceuticals, Inc. (Recursion Pharmaceuticals Inc) | Long | Equity-common | US | $56K | 8K | 0.51 |
| Regeneron Pharmaceuticals, Inc. (Regeneron Pharmaceuticals Inc) | Long | Equity-common | US | $465K | 442 | 4.24 |
| REVOLUTION Medicines, Inc. (REVOLUTION Medicines Inc) | Long | Equity-common | US | $125K | 3K | 1.14 |
| Roivant Sciences Ltd. | Long | Equity-common | US | $115K | 11K | 1.05 |
| Royalty Pharma plc | Long | Equity-common | US | $186K | 7K | 1.70 |
| Sage Therapeutics, Inc. (Sage Therapeutics Inc) | Long | Equity-common | US | $35K | 3K | 0.32 |
| Sarepta Therapeutics, Inc. (Sarepta Therapeutics Inc) | Long | Equity-common | US | $215K | 1K | 1.96 |
| SpringWorks Therapeutics, Inc. (SpringWorks Therapeutics Inc) | Long | Equity-common | US | $62K | 2K | 0.56 |
| TG Therapeutics, Inc. (TG Therapeutics Inc) | Long | Equity-common | US | $83K | 5K | 0.76 |
| Twist Bioscience Corp. | Long | Equity-common | US | $77K | 2K | 0.70 |
| Ultragenyx Pharmaceutical, Inc. (Ultragenyx Pharmaceutical Inc) | Long | Equity-common | US | $90K | 2K | 0.82 |
| United Therapeutics Corp. | Long | Equity-common | US | $201K | 631 | 1.83 |
| Vaxcyte, Inc. (Vaxcyte Inc) | Long | Equity-common | US | $125K | 2K | 1.14 |
| Vertex Pharmaceuticals, Inc. (Vertex Pharmaceuticals Inc) | Long | Equity-common | US | $445K | 949 | 4.06 |
| Viatris, Inc. (Viatris Inc) | Long | Equity-common | US | $185K | 17K | 1.68 |
| Viking Therapeutics, Inc. (Viking Therapeutics Inc) | Long | Equity-common | US | $121K | 2K | 1.10 |
Address
Rydex Variable Trust
702 King Farm Blvd., Suite 200
Rockville
Maryland
20850
United States of America
Directors
Randall C. Barnes
Sandra G. Sponem
Ronald E. Toupin, Jr.
Angela Brock-Kyle
Thomas F. Lydon Jr.
Amy J. Lee
Ronald A. Nyberg
Transfer Agents
MUFG Investor Services (US), LLC
Pricing Services
ICE Data Services
Custodians
U.S. Bank N.A.
Shareholder Servicing Agents
MUFG Investor Services (US), LLC
Admins
MUFG Investor Services (US), LLC
Brokers
BOFA SECURITIES, INC.
BARCLAYS CAPITAL INC.
Instinet, LLC
BTIG, LLC